Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat Media The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Reported by Chris Markoch. Date Posted: 1/18/2026. 
Key Points - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. Investors typically hunt for companies with disruptive technologies, exposure to emerging trends, or compelling turnaround stories. Many of these firms won't survive or scale, but if even one succeeds, the returns can be substantial. For those who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. That's not a guarantee of success, but it can help investors gain conviction in a stock's potential. Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund.
It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you."
This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story. Some define penny stocks as any shares trading for $5 or less, but the stocks in this screener follow the traditional definition: shares priced below $1. These stocks are highly volatile, so do your own research and assess your risk tolerance before taking a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases — including influenza, norovirus and COVID-19. Unlike traditional injected vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bullish case for Vaxart hinges on its novel approach. If Vaxart obtains FDA approval and can scale manufacturing and distribution, its oral vaccines could reduce logistical barriers to mass immunization and create attractive licensing opportunities. Positive trial results or a commercial collaboration could dramatically shift sentiment and valuation given the stock's current low base. Clinical risk is the biggest challenge. Vaxart has not yet brought a product to market, and vaccine development is expensive and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. MarketBeat's analyst coverage of Vaxart is minimal — only a single analyst currently follows the stock — which can be a warning sign for some investors. VXRT also has just 18% institutional ownership. On the plus side, the stock's short interest is only about 2%, which may remove some downward pressure on volatility. Microvision: Developing Cost-Effective LiDAR Units For Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors for autonomous vehicles, smart infrastructure, and industrial sensing. Its hardware and software enable the precise 3D mapping needed for self-driving systems and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision rests on continued progress toward vehicle automation and the prospect of partnerships with major automakers. If the company can demonstrate performance or cost advantages, it could land supply agreements or licensing deals that improve revenue visibility. Microvision's technology may also find applications in robotics and smart cities, adding optionality to its growth story. Despite the promise, Microvision faces stiff competition from LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ), and Ouster (NYSE: OUST). The path to profitability is uncertain, and recurring delays in commercial LiDAR adoption have frustrated investors. MVIS is covered by three analysts and has a consensus price target of $2.50 — roughly a 169% increase from its Jan. 15 closing price. Like many speculative names, Microvision also has relatively low institutional ownership (around 30%) and high short interest (around 21%), indicating the potential for significant volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization, and digital asset management. The company helps organizations convert raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain, and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems miss. The bullish thesis for Datavault AI centers on its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses — and potentially individuals — are looking for ways to safely monetize digital information. Datavault's technology could benefit from broader AI adoption and heightened interest in data sovereignty. Early traction or strategic partnerships could catalyze investor confidence. That said, Datavault AI operates in an experimental space. Its business model is still evolving, and the path to meaningful revenue growth is unproven. Institutions own less than 1% of the stock, and short interest is over 16% at the time of writing. Investors considering DVLT should treat it as a long-term speculative position based on belief in data-as-an-asset innovation rather than near-term earnings potential.
| 
